(NASDAQ: ABCL) Abcellera Biologics's forecast annual revenue growth rate of -22.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Abcellera Biologics's revenue in 2026 is $66,173,000.On average, 11 Wall Street analysts forecast ABCL's revenue for 2026 to be $7,927,746,065, with the lowest ABCL revenue forecast at $6,520,399,436, and the highest ABCL revenue forecast at $10,946,029,336. On average, 10 Wall Street analysts forecast ABCL's revenue for 2027 to be $9,087,963,852, with the lowest ABCL revenue forecast at $6,009,584,734, and the highest ABCL revenue forecast at $15,775,159,926.
In 2028, ABCL is forecast to generate $9,078,458,897 in revenue, with the lowest revenue forecast at $6,009,584,734 and the highest revenue forecast at $11,055,489,630.